- Home
- MYGN vs HGTY Comparison
MYGN vs HGTY Comparison
Compare MYGN & HGTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- HGTY
- Stock Information
- Founded
- MYGN 1991
- HGTY 1984
- Country
- MYGN United States
- HGTY United States
- Employees
- MYGN N/A
- HGTY N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- HGTY Specialty Insurers
- Sector
- MYGN Health Care
- HGTY Finance
- Exchange
- MYGN Nasdaq
- HGTY Nasdaq
- Market Cap
- MYGN 1.2B
- HGTY 995.8M
- IPO Year
- MYGN 1995
- HGTY N/A
- Fundamental
- Price
- MYGN $14.18
- HGTY $10.03
- Analyst Decision
- MYGN Hold
- HGTY Hold
- Analyst Count
- MYGN 13
- HGTY 3
- Target Price
- MYGN $22.54
- HGTY $11.00
- AVG Volume (30 Days)
- MYGN 1.2M
- HGTY 38.7K
- Earning Date
- MYGN 02-24-2025
- HGTY 03-11-2025
- Dividend Yield
- MYGN N/A
- HGTY N/A
- EPS Growth
- MYGN N/A
- HGTY N/A
- EPS
- MYGN N/A
- HGTY 0.11
- Revenue
- MYGN $823,600,000.00
- HGTY $1,153,350,000.00
- Revenue This Year
- MYGN $13.60
- HGTY $20.97
- Revenue Next Year
- MYGN $3.25
- HGTY $14.55
- P/E Ratio
- MYGN N/A
- HGTY $94.96
- Revenue Growth
- MYGN 12.15
- HGTY 21.13
- 52 Week Low
- MYGN $12.04
- HGTY $8.27
- 52 Week High
- MYGN $29.30
- HGTY $12.35
- Technical
- Relative Strength Index (RSI)
- MYGN 55.82
- HGTY 50.48
- Support Level
- MYGN $14.13
- HGTY $9.92
- Resistance Level
- MYGN $15.47
- HGTY $10.23
- Average True Range (ATR)
- MYGN 0.72
- HGTY 0.34
- MACD
- MYGN 0.27
- HGTY 0.02
- Stochastic Oscillator
- MYGN 61.38
- HGTY 58.67
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About HGTY Hagerty Inc.
Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically it serves Europe, Canada, and the United States.